NSG 554 FNP Exam 2 Test Bank | 2026/2027 Edition | 250
Verified Questions
NSG 554 FNP Exam 2 Review: 2026-2027 Questions and Answers Already Graded A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive test bank for NSG 554 Exam 2 at Wilkes University provides 250 verified
questions covering the core content areas of family nurse practitioner practice. Designed to mirror the
actual exam format, each question includes detailed rationales and evidence-based explanations.
Updated for the 2026/2027 academic year, this resource ensures students are fully prepared for the FNP
exam. Ideal for focused review and self-assessment.
Key Features:
250 verified questions with correct answers and rationales
Covers acute and chronic illness management across the lifespan
Includes pharmacology, diagnostic reasoning, and evidence-based practice
Reflects latest AANP and ANCC certification guidelines
Organized by content area for targeted study
Updates for 2026:
- Updated to reflect 2026/2027 clinical practice guidelines
- Revised rationales to include current evidence-based recommendations
- Added new questions on emerging health issues and pharmacotherapeutics
- Enhanced answer explanations with step-by-step clinical reasoning
Abstract:
This test bank is meticulously compiled to support mastery of NSG 554 FNP Exam 2 content. It encompasses 250
questions that assess knowledge across key domains: health promotion, disease prevention, diagnosis, and
management of common acute and chronic conditions. Each question is accompanied by a detailed rationale
explaining the correct answer and distractor analysis, promoting deep understanding. The content aligns with the
latest AANP and ANCC certification blueprints, ensuring relevance. This resource is essential for FNP students
seeking to consolidate their learning and achieve exam success. The questions are designed to challenge clinical
reasoning and application of evidence-based practice. By engaging with this material, students will enhance their
diagnostic and management skills. This test bank serves as a reliable tool for self-assessment and focused review.
Keywords:
NSG 554, FNP Exam 2, Wilkes University, test bank, family nurse practitioner, 250 questions, 2026/2027
Answer Format:
Each question is followed by the correct answer and a detailed rationale that explains the clinical reasoning behind
the choice. Distractors are analyzed to clarify common misconceptions. Rationales are referenced with current
evidence-based guidelines.
Compliance Checklist:
Aligned with 2026/2027 AANP and ANCC certification exam blueprints
Questions reviewed by subject matter experts for accuracy
Rationales cite current clinical practice guidelines and literature
Covers all major content areas as per NSG 554 syllabus
Updated to reflect latest pharmacologic and therapeutic recommendations
Content Area Overview:
Page 1
, Content Area Questions Key Topics Weight
Cardiovascular 1-50 hypertension, heart failure, coronary artery 20%
disease, dyslipidemia, arrhythmias
Respiratory 51-90 asthma, COPD, pneumonia, bronchitis, 16%
tuberculosis
Endocrine 91-130 diabetes mellitus, thyroid disorders, adrenal 16%
insufficiency, metabolic syndrome
Gastrointestinal 131-170 GERD, peptic ulcer disease, hepatitis, 16%
cirrhosis, irritable bowel syndrome
Neurology & Musculoskeletal 171-210 headache, stroke, back pain, osteoarthritis, 16%
fibromyalgia
Infectious Disease & 211-250 urinary tract infection, skin infections, HIV, 16%
Miscellaneous immunizations, health promotion
Page 2
,Q1. A patient with type 2 diabetes and stage 3 chronic kidney disease (eGFR 38 mL/min) has been
taking metformin 1000 mg twice daily. Recent labs show lactate 5.2 mmol/L (normal 0.5-2.2). What
is the most appropriate immediate action?
A. Continue metformin and monitor lactate in 1 week.
B. Reduce metformin dose to 500 mg twice daily.
C. Discontinue metformin and initiate insulin therapy.
D. Switch metformin to canagliflozin.
Correct Answer: C. Discontinue metformin and initiate insulin therapy.
Rationale: Metformin is contraindicated in patients with eGFR <30 mL/min and should be held in acute
kidney injury or conditions predisposing to lactic acidosis, such as elevated lactate. The lactate level
indicates possible lactic acidosis, requiring immediate discontinuation of metformin. Insulin is safe in
CKD and appropriate for glycemic control. Canagliflozin is not recommended when eGFR <45 mL/min.
Why Wrong:
A - Continuing metformin with elevated lactate risks progression of lactic acidosis.
B - Reducing dose does not address the contraindication in stage 3 CKD with elevated lactate.
D - Canagliflozin is contraindicated when eGFR <45 mL/min.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45.
Q2. A 55-year-old patient with hypertension and hyperlipidemia is started on atorvastatin 20 mg
daily. Three months later, LDL remains elevated. The patient reports occasional muscle aches but
no weakness or dark urine. Which of the following is the most appropriate next step?
A. Increase atorvastatin to 40 mg daily.
B. Switch to rosuvastatin 10 mg daily.
C. Add ezetimibe 10 mg daily.
D. Check creatine kinase level before adjusting therapy.
Correct Answer: D. Check creatine kinase level before adjusting therapy.
Rationale: Before escalating statin therapy in a patient with muscle symptoms, it is essential to rule out
myopathy by measuring CK. If CK is normal, symptoms may be benign and therapy can be adjusted.
Increasing dose or switching without evaluation risks adverse effects. Adding ezetimibe is an option after
safety is confirmed.
Why Wrong:
A - Increasing dose without ruling out myopathy may worsen muscle symptoms.
B - Switching without CK check could still lead to myopathy with another statin.
C - Adding ezetimibe is appropriate only after confirming no contraindication to statin therapy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 37.
Page 3
, Q3. A patient with chronic heart failure (NYHA class III) and left ventricular ejection fraction 30%
is on lisinopril, metoprolol succinate, and furosemide. Despite adherence, the patient has persistent
dyspnea and edema. Which medication adjustment is most likely to improve outcomes?
A. Increase furosemide dose.
B. Add spironolactone 25 mg daily.
C. Increase metoprolol succinate dose.
D. Add digoxin 0.125 mg daily.
Correct Answer: B. Add spironolactone 25 mg daily.
Rationale: Guidelines recommend adding an aldosterone antagonist (e.g., spironolactone) in patients
with NYHA class II-IV HFrEF who remain symptomatic despite ACE inhibitor and beta-blocker therapy.
Spironolactone reduces mortality and hospitalizations. Furosemide dose adjustment may relieve
symptoms but does not improve survival. Digoxin is reserved for refractory symptoms or atrial
fibrillation.
Why Wrong:
A - Increasing furosemide may relieve symptoms but does not reduce mortality.
C - Maximizing beta-blocker is important, but adding spironolactone is the next evidence-based step.
D - Digoxin is a second- or third-line agent for symptomatic HFrEF.
Reference: Yancy, C.W., et al. (2017). ACC/AHA/HFSA Focused Update on Heart Failure. Circulation,
136(6).
Q4. A patient with asthma is using a high-dose inhaled corticosteroid (ICS) and a long-acting
beta-agonist (LABA) but still requires rescue inhaler more than twice weekly. Which of the
following reflects the current GINA guidelines step-up approach?
A. Increase ICS to very high dose.
B. Add a leukotriene receptor antagonist.
C. Add a long-acting muscarinic antagonist (LAMA).
D. Refer for biologic therapy (e.g., omalizumab).
Correct Answer: C. Add a long-acting muscarinic antagonist (LAMA).
Rationale: GINA 2024 recommends adding LAMA (e.g., tiotropium) for patients with uncontrolled
asthma on ICS/LABA combination. This is the preferred step-up before considering biologics. Increasing
ICS to very high dose has limited additional benefit and increases side effects. Leukotriene receptor
antagonists are less effective than LAMA as add-on. Biologics are reserved for severe allergic or
eosinophilic asthma.
Why Wrong:
A - Very high dose ICS offers minimal additional benefit with increased risk of side effects.
B - Leukotriene receptor antagonists are less effective than LAMA as add-on therapy.
D - Biologics are indicated only for severe asthma with specific phenotypes.
Reference: Global Initiative for Asthma (GINA). (2024). Global Strategy for Asthma Management and
Prevention.
Page 4
Verified Questions
NSG 554 FNP Exam 2 Review: 2026-2027 Questions and Answers Already Graded A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive test bank for NSG 554 Exam 2 at Wilkes University provides 250 verified
questions covering the core content areas of family nurse practitioner practice. Designed to mirror the
actual exam format, each question includes detailed rationales and evidence-based explanations.
Updated for the 2026/2027 academic year, this resource ensures students are fully prepared for the FNP
exam. Ideal for focused review and self-assessment.
Key Features:
250 verified questions with correct answers and rationales
Covers acute and chronic illness management across the lifespan
Includes pharmacology, diagnostic reasoning, and evidence-based practice
Reflects latest AANP and ANCC certification guidelines
Organized by content area for targeted study
Updates for 2026:
- Updated to reflect 2026/2027 clinical practice guidelines
- Revised rationales to include current evidence-based recommendations
- Added new questions on emerging health issues and pharmacotherapeutics
- Enhanced answer explanations with step-by-step clinical reasoning
Abstract:
This test bank is meticulously compiled to support mastery of NSG 554 FNP Exam 2 content. It encompasses 250
questions that assess knowledge across key domains: health promotion, disease prevention, diagnosis, and
management of common acute and chronic conditions. Each question is accompanied by a detailed rationale
explaining the correct answer and distractor analysis, promoting deep understanding. The content aligns with the
latest AANP and ANCC certification blueprints, ensuring relevance. This resource is essential for FNP students
seeking to consolidate their learning and achieve exam success. The questions are designed to challenge clinical
reasoning and application of evidence-based practice. By engaging with this material, students will enhance their
diagnostic and management skills. This test bank serves as a reliable tool for self-assessment and focused review.
Keywords:
NSG 554, FNP Exam 2, Wilkes University, test bank, family nurse practitioner, 250 questions, 2026/2027
Answer Format:
Each question is followed by the correct answer and a detailed rationale that explains the clinical reasoning behind
the choice. Distractors are analyzed to clarify common misconceptions. Rationales are referenced with current
evidence-based guidelines.
Compliance Checklist:
Aligned with 2026/2027 AANP and ANCC certification exam blueprints
Questions reviewed by subject matter experts for accuracy
Rationales cite current clinical practice guidelines and literature
Covers all major content areas as per NSG 554 syllabus
Updated to reflect latest pharmacologic and therapeutic recommendations
Content Area Overview:
Page 1
, Content Area Questions Key Topics Weight
Cardiovascular 1-50 hypertension, heart failure, coronary artery 20%
disease, dyslipidemia, arrhythmias
Respiratory 51-90 asthma, COPD, pneumonia, bronchitis, 16%
tuberculosis
Endocrine 91-130 diabetes mellitus, thyroid disorders, adrenal 16%
insufficiency, metabolic syndrome
Gastrointestinal 131-170 GERD, peptic ulcer disease, hepatitis, 16%
cirrhosis, irritable bowel syndrome
Neurology & Musculoskeletal 171-210 headache, stroke, back pain, osteoarthritis, 16%
fibromyalgia
Infectious Disease & 211-250 urinary tract infection, skin infections, HIV, 16%
Miscellaneous immunizations, health promotion
Page 2
,Q1. A patient with type 2 diabetes and stage 3 chronic kidney disease (eGFR 38 mL/min) has been
taking metformin 1000 mg twice daily. Recent labs show lactate 5.2 mmol/L (normal 0.5-2.2). What
is the most appropriate immediate action?
A. Continue metformin and monitor lactate in 1 week.
B. Reduce metformin dose to 500 mg twice daily.
C. Discontinue metformin and initiate insulin therapy.
D. Switch metformin to canagliflozin.
Correct Answer: C. Discontinue metformin and initiate insulin therapy.
Rationale: Metformin is contraindicated in patients with eGFR <30 mL/min and should be held in acute
kidney injury or conditions predisposing to lactic acidosis, such as elevated lactate. The lactate level
indicates possible lactic acidosis, requiring immediate discontinuation of metformin. Insulin is safe in
CKD and appropriate for glycemic control. Canagliflozin is not recommended when eGFR <45 mL/min.
Why Wrong:
A - Continuing metformin with elevated lactate risks progression of lactic acidosis.
B - Reducing dose does not address the contraindication in stage 3 CKD with elevated lactate.
D - Canagliflozin is contraindicated when eGFR <45 mL/min.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45.
Q2. A 55-year-old patient with hypertension and hyperlipidemia is started on atorvastatin 20 mg
daily. Three months later, LDL remains elevated. The patient reports occasional muscle aches but
no weakness or dark urine. Which of the following is the most appropriate next step?
A. Increase atorvastatin to 40 mg daily.
B. Switch to rosuvastatin 10 mg daily.
C. Add ezetimibe 10 mg daily.
D. Check creatine kinase level before adjusting therapy.
Correct Answer: D. Check creatine kinase level before adjusting therapy.
Rationale: Before escalating statin therapy in a patient with muscle symptoms, it is essential to rule out
myopathy by measuring CK. If CK is normal, symptoms may be benign and therapy can be adjusted.
Increasing dose or switching without evaluation risks adverse effects. Adding ezetimibe is an option after
safety is confirmed.
Why Wrong:
A - Increasing dose without ruling out myopathy may worsen muscle symptoms.
B - Switching without CK check could still lead to myopathy with another statin.
C - Adding ezetimibe is appropriate only after confirming no contraindication to statin therapy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 37.
Page 3
, Q3. A patient with chronic heart failure (NYHA class III) and left ventricular ejection fraction 30%
is on lisinopril, metoprolol succinate, and furosemide. Despite adherence, the patient has persistent
dyspnea and edema. Which medication adjustment is most likely to improve outcomes?
A. Increase furosemide dose.
B. Add spironolactone 25 mg daily.
C. Increase metoprolol succinate dose.
D. Add digoxin 0.125 mg daily.
Correct Answer: B. Add spironolactone 25 mg daily.
Rationale: Guidelines recommend adding an aldosterone antagonist (e.g., spironolactone) in patients
with NYHA class II-IV HFrEF who remain symptomatic despite ACE inhibitor and beta-blocker therapy.
Spironolactone reduces mortality and hospitalizations. Furosemide dose adjustment may relieve
symptoms but does not improve survival. Digoxin is reserved for refractory symptoms or atrial
fibrillation.
Why Wrong:
A - Increasing furosemide may relieve symptoms but does not reduce mortality.
C - Maximizing beta-blocker is important, but adding spironolactone is the next evidence-based step.
D - Digoxin is a second- or third-line agent for symptomatic HFrEF.
Reference: Yancy, C.W., et al. (2017). ACC/AHA/HFSA Focused Update on Heart Failure. Circulation,
136(6).
Q4. A patient with asthma is using a high-dose inhaled corticosteroid (ICS) and a long-acting
beta-agonist (LABA) but still requires rescue inhaler more than twice weekly. Which of the
following reflects the current GINA guidelines step-up approach?
A. Increase ICS to very high dose.
B. Add a leukotriene receptor antagonist.
C. Add a long-acting muscarinic antagonist (LAMA).
D. Refer for biologic therapy (e.g., omalizumab).
Correct Answer: C. Add a long-acting muscarinic antagonist (LAMA).
Rationale: GINA 2024 recommends adding LAMA (e.g., tiotropium) for patients with uncontrolled
asthma on ICS/LABA combination. This is the preferred step-up before considering biologics. Increasing
ICS to very high dose has limited additional benefit and increases side effects. Leukotriene receptor
antagonists are less effective than LAMA as add-on. Biologics are reserved for severe allergic or
eosinophilic asthma.
Why Wrong:
A - Very high dose ICS offers minimal additional benefit with increased risk of side effects.
B - Leukotriene receptor antagonists are less effective than LAMA as add-on therapy.
D - Biologics are indicated only for severe asthma with specific phenotypes.
Reference: Global Initiative for Asthma (GINA). (2024). Global Strategy for Asthma Management and
Prevention.
Page 4
